577 related articles for article (PubMed ID: 10913394)
1. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
2. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
3. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
[TBL] [Abstract][Full Text] [Related]
4. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum.
Wagner B; Freer H; Rollins A; Erb HN
Vet Immunol Immunopathol; 2011 Apr; 140(3-4):190-8. PubMed ID: 21208663
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
6. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
[TBL] [Abstract][Full Text] [Related]
7. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
8. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
[TBL] [Abstract][Full Text] [Related]
9. Growth-inhibiting antibody responses of humans vaccinated with recombinant outer surface protein A or infected with Borrelia burgdorferi or both.
Luke CJ; Marshall MA; Zahradnik JM; Bybel M; Menefee BE; Barbour AG
J Infect Dis; 2000 Mar; 181(3):1062-8. PubMed ID: 10720532
[TBL] [Abstract][Full Text] [Related]
10. Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in horses and its validation using Bayesian and conventional statistical methods.
Wagner B; Freer H; Rollins A; Erb HN; Lu Z; Gröhn Y
Vet Immunol Immunopathol; 2011 Dec; 144(3-4):374-81. PubMed ID: 21890217
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
12. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
13. Detection of Lyme disease after OspA vaccine.
Schutzer SE; Luan J; Coyle PK
N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
[No Abstract] [Full Text] [Related]
14. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different Borrelia burgdorferi sensu lato strains for detection of immune response in patients with erythema migrans.
Merljak Skocir L; Ruzić-Sabljić E; Maraspin-Carman V; Lotric-Furlan S; Logar M; Strle F
Int J Med Microbiol; 2008 Jul; 298(5-6):493-504. PubMed ID: 17892971
[TBL] [Abstract][Full Text] [Related]
17. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice.
Bockenstedt LK; Fikrig E; Barthold SW; Kantor FS; Flavell RA
J Immunol; 1993 Jul; 151(2):900-6. PubMed ID: 8335917
[TBL] [Abstract][Full Text] [Related]
18. Effects of OspA vaccination on Lyme disease serologic testing.
Aguero-Rosenfeld ME; Roberge J; Carbonaro CA; Nowakowski J; Nadelman RB; Wormser GP
J Clin Microbiol; 1999 Nov; 37(11):3718-21. PubMed ID: 10523583
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.
Ledue TB; Collins MF; Young J; Schriefer ME
Clin Vaccine Immunol; 2008 Dec; 15(12):1796-804. PubMed ID: 18945880
[TBL] [Abstract][Full Text] [Related]
20. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
